676 related articles for article (PubMed ID: 26316560)
1. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
Cardona AF; Wilson SE
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
[TBL] [Abstract][Full Text] [Related]
2. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
Tsoulas C; Nathwani D
Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
[TBL] [Abstract][Full Text] [Related]
3. Hospitalist perspective on the treatment of skin and soft tissue infections.
Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM
Mayo Clin Proc; 2014 Oct; 89(10):1436-51. PubMed ID: 24974260
[TBL] [Abstract][Full Text] [Related]
4. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
5. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
6. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria.
Stevens DL
J Infect; 2009 Sep; 59 Suppl 1():S32-9. PubMed ID: 19766887
[TBL] [Abstract][Full Text] [Related]
7. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
8. Severe soft tissue infections.
Napolitano LM
Infect Dis Clin North Am; 2009 Sep; 23(3):571-91. PubMed ID: 19665084
[TBL] [Abstract][Full Text] [Related]
9. Treatment of infections due to resistant Staphylococcus aureus.
Anstead GM; Cadena J; Javeri H
Methods Mol Biol; 2014; 1085():259-309. PubMed ID: 24085702
[TBL] [Abstract][Full Text] [Related]
10. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
11. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
12. The times they are a-changin': new antibacterials for skin and skin structure infections.
Tran MC; Naumovski S; Goldstein EJ
Am J Clin Dermatol; 2015 Jun; 16(3):137-46. PubMed ID: 25906205
[TBL] [Abstract][Full Text] [Related]
13. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Twilla JD; Gelfand MS; Cleveland KO; Usery JB
J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
[No Abstract] [Full Text] [Related]
14. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines.
Moran GJ; Abrahamian FM; Lovecchio F; Talan DA
J Emerg Med; 2013 Jun; 44(6):e397-412. PubMed ID: 23466022
[TBL] [Abstract][Full Text] [Related]
15. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
16. Treatment of infections caused by resistant Staphylococcus aureus.
Anstead GM; Quinones-Nazario G; Lewis JS
Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681
[TBL] [Abstract][Full Text] [Related]
17. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
18. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
19. Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?
Grupper M; Nicolau DP
Curr Opin Infect Dis; 2017 Apr; 30(2):180-191. PubMed ID: 28118218
[TBL] [Abstract][Full Text] [Related]
20. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
